Ocular delivery of solid lipid nanoparticles

Battaglia, Luigi; Gallarate, Marina; Serpe, Loredana; Foglietta, Federica; Muntoni, Elisabetta; Rodríguez, Ana del Pozo; Aspiazu, María Ángeles Solinís

doi:10.1016/b978-0-12-813687-4.00007-4

Cited by 14 publications

(15 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PVA has been widely used because of its muco-mimetic properties, high water retention capacity, oxygen permeability, and low toxicity [55]. These properties confer to our nanosystems the ability to increase the residence time, and consequently improve the ocular bioavailability, reducing the drainage from lachrymal fluid [56,57]. In early studies, our group showed that the combination of SLN-based vectors with PVA provided a higher retention on the cornea [32].…”

Section: Discussionmentioning

confidence: 99%

mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation

et al. 2021

Self Cite

View full text Add to dashboard Cite

The anti-inflammatory cytokine Interleukin-10 (IL-10) is considered an efficient treatment for corneal inflammation, in spite of its short half-life and poor eye bioavailability. In the present work, mRNA-based nanomedicinal products based on solid lipid nanoparticles (SLNs) were developed in order to produce IL-10 to treat corneal inflammation. mRNA encoding green fluorescent protein (GFP) or human IL-10 was complexed with different SLNs and ligands. After, physicochemical characterization, transfection efficacy, intracellular disposition, cellular uptake and IL-10 expression of the nanosystems were evaluated in vitro in human corneal epithelial (HCE-2) cells. Energy-dependent mechanisms favoured HCE-2 transfection, whereas protein production was influenced by energy-independent uptake mechanisms. Nanovectors with a mean particle size between 94 and 348 nm and a positive superficial charge were formulated as eye drops containing 1% (w/v) of polyvinyl alcohol (PVA) with 7.1–7.5 pH. After three days of topical administration to mice, all formulations produced GFP in the corneal epithelium of mice. SLNs allowed the obtaining of a higher transfection efficiency than naked mRNA. All formulations produce IL-10, and the interleukin was even observed in the deeper layers of the epithelium of mice depending on the formulation. This work shows the potential application of mRNA-SLN-based nanosystems to address corneal inflammation by gene augmentation therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the retro bulbar route the formulation is injected into the eyelid and orbital fascia for deposition of the drug behind the globe in the retrobulbar space [17]. However, this route is not much preferred as it may damage the orbital structure of the optic nerve [24,25]. The sub-retinal route is used to deliver the drug directly to the outer retina for management of the retinal degenerations, which originate in the photoreceptors and RPE [26,27].…”

Section: Local Routementioning

confidence: 99%

Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems

et al. 2021

View full text Add to dashboard Cite

One of the major impediments to drug development is low aqueous solubility and thus poor bioavailability, which leads to insufficient clinical utility. Around 70–80% of drugs in the discovery pipeline are suffering from poor aqueous solubility and poor bioavailability, which is a major challenge when one has to develop an ocular drug delivery system. The outer lipid layer, pre-corneal, dynamic, and static ocular barriers limit drug availability to the targeted ocular tissues. Biopharmaceutical Classification System (BCS) class II drugs with adequate permeability and limited or no aqueous solubility have been extensively studied for various polymer-based solubility enhancement approaches. The hydrophilic nature of cellulosic polymers and their tunable properties make them the polymers of choice in various solubility-enhancement techniques. This review focuses on various cellulose derivatives, specifically, their role, current status and novel modified cellulosic polymers for enhancing the bioavailability of BCS class II drugs in ocular drug delivery systems.

show abstract

“…Furthermore, this therapeutic modality necessitates frequent monthly or bi-monthly delivery [ 23 ] as the administered drug has a short retention time, primarily due to the high protein clearance rates from the ocular humor [ 85 ]. Intravitreal injections of VEGF inhibitors have been reported to present decreased bioavailability of the drug due to restricted ocular space, lachrymal drainage, and ocular enzymatic degradation [ 102 , 103 ]. Studies suggest that several ocular complications such as intraocular hemorrhage, RPE tear, increased intraocular pressure, inflammation, vitreous bleeding, and retinal detachment may occur [ 104 ].…”

Section: Advanced Therapeutics and Delivery Strategies For Namdmentioning

confidence: 99%

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Sarkar

Junnuthula

Dyawanapelly

2021

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies.

show abstract

Ocular delivery of solid lipid nanoparticles

Cited by 14 publications

References 154 publications

mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation

mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation

Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Contact Info

Product

Resources

About